Pharmaceutical Firm Lupeng Biotech Files for Hong Kong IPO Again

Stock News

May 28

According to a disclosure by the Hong Kong Stock Exchange on May 28, Lupeng Pharmaceutical Co., Ltd. (referred to as Lupeng Biotech) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities serving as the exclusive sponsor. The company had previously filed for a listing on October 31, 2025. Lupeng Biotech is a biopharmaceutical company that possesses its self-developed BeyondX oral drug chemistry platform, focusing on designing, discovering, clinically developing, and commercializing high-bioavailability oral drugs for global cancer and autoimmune disease patients. The company has established a product pipeline comprising six major candidate products, three of which are core assets in the new drug application and clinical stages, namely the core products LP-168, LP-108, and LP-118.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1198145597"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198145597\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198145597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198145597","market":"nz","top_or_hot":-1,"title":"Pharmaceutical Firm Lupeng Biotech Files for Hong Kong IPO Again","media":"Stock News","content":"<p>According to a disclosure by the Hong Kong Stock Exchange on May 28, Lupeng Pharmaceutical Co., Ltd. (referred to as Lupeng Biotech) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities serving as the exclusive sponsor. The company had previously filed for a listing on October 31, 2025. Lupeng Biotech is a biopharmaceutical company that possesses its self-developed BeyondX oral drug chemistry platform, focusing on designing, discovering, clinically developing, and commercializing high-bioavailability oral drugs for global cancer and autoimmune disease patients. The company has established a product pipeline comprising six major candidate products, three of which are core assets in the new drug application and clinical stages, namely the core products LP-168, LP-108, and LP-118.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaceutical Firm Lupeng Biotech Files for Hong Kong IPO Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaceutical Firm Lupeng Biotech Files for Hong Kong IPO Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-28 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a disclosure by the Hong Kong Stock Exchange on May 28, Lupeng Pharmaceutical Co., Ltd. (referred to as Lupeng Biotech) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities serving as the exclusive sponsor. The company had previously filed for a listing on October 31, 2025. Lupeng Biotech is a biopharmaceutical company that possesses its self-developed BeyondX oral drug chemistry platform, focusing on designing, discovering, clinically developing, and commercializing high-bioavailability oral drugs for global cancer and autoimmune disease patients. The company has established a product pipeline comprising six major candidate products, three of which are core assets in the new drug application and clinical stages, namely the core products LP-168, LP-108, and LP-118.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1198145597","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198145597","pubTimestamp":1779965311,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to a disclosure by the Hong Kong Stock Exchange on May 28, Lupeng Pharmaceutical Co., Ltd. (referred to as Lupeng Biotech) has submitted an application for listing on the main board of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","IPOS":"Renaissance International IPO ETF","01477":"欧康维视生物-B","BK1574":"生物医药B类股"},"translate_title":"药企绿鹏生物再次申请香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"01477":1,"HEXmain":1},"content_text":"According to a disclosure by the Hong Kong Stock Exchange on May 28, Lupeng Pharmaceutical Co., Ltd. (referred to as Lupeng Biotech) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities serving as the exclusive sponsor. The company had previously filed for a listing on October 31, 2025. Lupeng Biotech is a biopharmaceutical company that possesses its self-developed BeyondX oral drug chemistry platform, focusing on designing, discovering, clinically developing, and commercializing high-bioavailability oral drugs for global cancer and autoimmune disease patients. The company has established a product pipeline comprising six major candidate products, three of which are core assets in the new drug application and clinical stages, namely the core products LP-168, LP-108, and LP-118.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}